N1BI34:BVMF
Neurocrine Biosciences Bdr
R$47.20
arrow_downward
-1.56%(-0.75) 1D
Nov 19, 5:29:53 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for N1BI34...
Open
R$50.00
High
R$50.00
Low
R$46.15
Mkt. cap
15.85B
Avg. vol.
1.75K
Volume
0.00
52-wk high
R$50.00
52-wk low
R$31.51
Shares outstanding
101.22M
No. of employees
2K
Open
R$50.00
High
R$50.00
Low
R$46.15
Mkt. cap
15.85B
Avg. vol.
1.75K
Volume
0.00
52-wk high
R$50.00
52-wk low
R$31.51
Shares outstanding
101.22M
No. of employees
2K
News stories
From web sources and news partners
Investing.com Canada
·
5 hours ago
Neurocrine Biosciences director Gary Lyons sells $2.47M in shares By Investing.com
Yahoo Finance
·
1 day ago
Neurocrine Biosciences (NBIX) Stock Still Looks Undervalued As Its 89% Run Draws Focus
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences Bdr
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteneurocrine.com